<DOC>
	<DOCNO>NCT01173601</DOCNO>
	<brief_summary>The primary purpose study ass whether least one dose LY2216684 ( 12 mg 18 mg daily ) superior placebo daily adjunctive treatment patient major depressive disorder ( MDD ) identify partial responder adequate course treatment selective serotonin reuptake inhibitor ( SSRI ) , 11-week , double-blind , acute adjunctive treatment phase .</brief_summary>
	<brief_title>A Fixed Dose Study Adjunctive Treatment Antidepressant Therapy Adults With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Clinical diagnosis Major Depressive Disorder ( MDD ) Women childbearing potential may participate must test negative pregnancy time study entry ; women/men agree use reliable method birth control Are take SSRI approve MDD treatment within patient 's country SSRI prescribe , include dose , consistent label guideline within participate country Have partial response SSRI treatment Meet inclusion score predefined psychiatric scale assess diagnosis depression , disease severity , response SSRI treatment Reliable able keep schedule appointment Presence another primary psychiatric illness : Have currently additional ongoing Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) Axis 1 condition major depression within 1 year screening Have anxiety disorder consider primary diagnosis within past year ( include panic disorder , obsessivecompulsive disorder , posttraumatic stress disorder , generalize anxiety disorder , social phobia , exclude specific phobia ) Have current previous diagnosis bipolar disorder , schizophrenia , psychotic disorder Have history substance abuse and/or dependence within past 1 year ( drug category define DSMIVTR ) , include caffeine nicotine . Have Axis II disorder , judgment investigator , would interfere compliance protocol Have diagnose medical condition could exacerbate noradrenergic agent include unstable hypertension , unstable heart disease , tachycardia , tachyarrhythmia , narrowangle glaucoma , urinary hesitation retention Use exclude concomitant psychotropic medication SSRI Have initiate discontinue hormone therapy within previous 3 month prior enrollment Have treatment resistant depression Have lifetime history vagal nerve stimulation , transcranial magnetic stimulation , psychosurgery Have receive electroconvulsive therapy last year Enrollment clinical study investigational drug Serious unstable medical condition History seizure disorder Have initiate psychotherapy nondrug therapy ( acupuncture hypnosis ) within 12 week prior enrollment time study . No change intensity psychotherapy within last 6 week prior enrollment time study . Patients , opinion investigator , judge serious risk harm self others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>